Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.27 +0.16 (+0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SpringWorks Therapeutics, Inc. - common stock

< Previous 1 2 3 4 5 6 Next >
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in... 
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics: Q4 Earnings Insights
Via Benzinga
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Near the Top of Equities by Percentage Gain on 11/30
Via Investor Brand Network
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Near the Top of Equities by Percentage Gain on 11/28
Via Investor Brand Network
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving
SpringWorks Therapeutics Inc (NASDAQ: SWTX) shares are trading lower by 8.4% to $29.00 Tuesday morning after the company announced the pricing of a publ 
Via Benzinga
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results. 
Via Benzinga
La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment
The company gained FDA approval for Ogsiveo, a treatment for desmoid tumors. 
Via Investor's Business Daily
Exposures Product Safety
PDD Posts Upbeat Revenue, Joins Avidity Biosciences, SpringWorks Therapeutics And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
Via Benzinga
Exposures Product Safety
FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas
The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who  
Via Benzinga
Exposures Product Safety
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know
Via Benzinga
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today?
SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with... 
Via Benzinga
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.